- the nation". In
March 2011, TransMolecular's ****ets were
purchased by
Morphotek, a
subsidiary of the ****anese
pharmaceutical company Eisai. McIntosh,...
-
monoclonal antibody designed for the
treatment of cancer. It was
developed by
Morphotek, Inc.
Amatuximab is a
monoclonal antibody that
binds to
mesothelin (a...
- Pharmaceuticals. In
April 2007,
Eisai acquired Exton, Pennsylvania-based
Morphotek, a
company developing therapeutic monoclonal antibodies for the treatment...
-
colorectal cancer, sarcoma, and lymphoma. This drug was
developed by
Morphotek and
Ludwig Institute for
Cancer Research.
World Health Organization (2013)...
-
investigated for the
treatment of
ovarian cancer. This drug was
developed by
Morphotek, Inc. It is
targeted at
folate receptor alpha (FRĪ±)
which is overexpressed...
-
Pharmaceuticals (merged with Biogen), LigoCyte,
Micromet (formerly CancerVax),
Morphotek (Acquired by
Eisai Corporation),
Sequana Therapeutics (merged with Arris...
- (farletuzumab),
currently in a
phase III
trial for
ovarian cancer sponsored by
Morphotek,
which licensed the
antibody from LICR. MORAb-003
targets the
folate receptor...
